These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22380743)

  • 1. Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin.
    Jensen BP; Chin PK; Roberts RL; Begg EJ
    Br J Clin Pharmacol; 2012 Nov; 74(5):797-805. PubMed ID: 22380743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
    Lane S; Al-Zubiedi S; Hatch E; Matthews I; Jorgensen AL; Deloukas P; Daly AK; Park BK; Aarons L; Ogungbenro K; Kamali F; Hughes D; Pirmohamed M
    Br J Clin Pharmacol; 2012 Jan; 73(1):66-76. PubMed ID: 21692828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
    Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
    J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.
    Wu JC; Nafziger AN; Bertino JS; Ma JD
    Drug Metab Lett; 2012 Jun; 6(2):94-101. PubMed ID: 22594566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
    Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.
    Linder MW; Looney S; Adams JE; Johnson N; Antonino-Green D; Lacefield N; Bukaveckas BL; Valdes R
    J Thromb Thrombolysis; 2002 Dec; 14(3):227-32. PubMed ID: 12913403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
    Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
    Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.
    Xue L; Holford N; Ding XL; Shen ZY; Huang CR; Zhang H; Zhang JJ; Guo ZN; Xie C; Zhou L; Chen ZY; Liu LS; Miao LY
    Br J Clin Pharmacol; 2017 Apr; 83(4):823-835. PubMed ID: 27763679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.
    Hamberg AK; Wadelius M; Lindh JD; Dahl ML; Padrini R; Deloukas P; Rane A; Jonsson EN
    Clin Pharmacol Ther; 2010 Jun; 87(6):727-34. PubMed ID: 20410877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Any effect of CYP2C9 variants on warfarin clearance in Chinese patients?
    You JH; Zuo Z; Lo CM; Zhou L; Yiu HH; Chau CT; Choi KC; Choi DK; Wong RS; Cheng G
    Thromb Haemost; 2007 May; 97(5):866-8. PubMed ID: 17479200
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
    Flora DR; Rettie AE; Brundage RC; Tracy TS
    J Clin Pharmacol; 2017 Mar; 57(3):382-393. PubMed ID: 27539372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation.
    Borgman MP; Pendleton RC; McMillin GA; Reynolds KK; Vazquez S; Freeman A; Wilson A; Valdes R; Linder MW
    Thromb Haemost; 2012 Sep; 108(3):561-9. PubMed ID: 22836303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.